Bicycle Therapeutics Newsroom

First Solar, Frontier Communications, and More Stocks See Action From Activist Investors -- Barrons.com

Barron'sDec 21 04:27

Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday

BenzingaDec 18 23:20

Bicycle Therapeutics Is Maintained at Market Outperform by JMP Securities

Dow JonesDec 18 22:35 · Ratings

JMP Securities Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Cuts Target Price to $26

Futu NewsDec 18 14:31 · Ratings

Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC), Incyte (INCY) and Bicycle Therapeutics (BCYC)

TipRanksDec 18 13:40 · Ratings

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (ZTS), Walgreens Boots Alliance (WBA) and Bicycle Therapeutics (BCYC)

TipRanksDec 18 13:30 · Ratings

Bicycle Therapeutics(BCYC.US) 10% Shareholder Buys US$21.23 Million in Common Stock

$Bicycle Therapeutics(BCYC.US)$ 10% Shareholder BAKER BROS. ADVISORS LP purchased 1.49 million shares of common stock on Dec 13, 16, 2024 at an average price of $14.2927 for a total value of $21.23

Futu NewsDec 18 07:09

Baker Bros. Advisors Increases Stake in Bicycle Therapeutics With $21.2 Million Purchase

InvestingDec 18 07:08

Breaking Down Bicycle Therapeutics: 8 Analysts Share Their Views

BenzingaDec 17 02:00

European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading

MT NewswiresDec 17 00:10

H.C. Wainwright Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Cuts Target Price to $33

Futu NewsDec 16 20:30 · Ratings

Barclays Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $40

Futu NewsDec 16 19:31 · Ratings

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Bicycle Therapeutics (BCYC) and Quest Diagnostics (DGX)

TipRanksDec 16 19:30 · Ratings

Morgan Stanley Maintains Bicycle Therapeutics(BCYC.US) With Hold Rating, Maintains Target Price $30

Futu NewsDec 14 07:31 · Ratings

Needham Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Cuts Target Price to $32

Futu NewsDec 14 05:32 · Ratings

ADRs End Higher; WISeKey International Holding Ltd. Climbs 139%

Dow JonesDec 14 05:31

Sector Update: Health Care Stocks Edge Higher Late Afternoon

MT NewswiresDec 14 04:59

Sector Update: Health Care

MT NewswiresDec 14 04:32

Bicycle Therapeutics Reports Updates Across Zelenectide Pevedotin Program; Shares Slump

MT NewswiresDec 14 02:53

Bicycle Therapeutics' Latest Trial Results Raise Questions -- Market Talk

WSJDec 14 02:19